1
|
Zimmermann O, Homann JM, Bangert A, Müller AM, Hristov G, Goeser S, Wiehe JM, Zittrich S, Rottbauer W, Torzewski J, Pfitzer G, Katus HA, Kaya Z. Successful use of mRNA-nucleofection for overexpression of interleukin-10 in murine monocytes/macrophages for anti-inflammatory therapy in a murine model of autoimmune myocarditis. J Am Heart Assoc 2012; 1:e003293. [PMID: 23316321 PMCID: PMC3540678 DOI: 10.1161/jaha.112.003293] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2012] [Accepted: 10/09/2012] [Indexed: 12/14/2022]
Abstract
Background Overexpression of interleukin-10 (IL-10) in murine CD11b+ monocytes/macrophages via GMP-adapted mRNA-nucleofection was expected to improve clinical outcome and reduce adverse side effects in autoimmune myocarditis. This study represents the proof of principle for a novel anti-inflammatory therapy using overexpression of IL-10 in murine monocytes/macrophages by mRNA-nucleofection for the treatment of autoimmune myocarditis. Methods and Results Autoimmune myocarditis was induced in A/J mice by subcutaneous immunization with troponin I. CD11b+ monocytes/macrophages were isolated from the peritoneum and IL-10 was overexpressed by mRNA-nucleofection. These cells were injected intravenously. Myocardial inflammation was assessed via histological and immunohistochemical examinations. Myocardial fibrosis was analyzed with Masson's trichrome staining. Antitroponin I antibodies were determined within the serum. Physical performance was evaluated using a running wheel and echocardiography. In vitro overexpression of IL-10 in CD11b+ monocytes/macrophages resulted in a 7-fold increased production of IL-10 (n=3). In vivo higher levels of IL-10 and less inflammation were detected within the myocardium of treated compared with control mice (n=4). IL-10–treated mice showed lower antitroponin I antibodies (n=10) and a better physical performance (n=10). Conclusions Application of IL-10–overexpressing CD11b+ monocytes/macrophages reduced inflammation and improved physical performance in a murine model of autoimmune myocarditis. Thus, the use of genetically modified monocytes/macrophages facilitated a targeted therapy of local inflammation and may reduce systemic side effects. Because the nucleofection technique is GMP adapted, an in vivo use in humans seems basically feasible and the transfer to other inflammatory diseases seems likely.
Collapse
|
2
|
Zimmermann O, Rodewald C, Radermacher M, Vetter M, Wiehe JM, Bienek-Ziolkowski M, Hombach V, Torzewski J. Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy? J Card Fail 2010; 16:348-56. [PMID: 20350703 DOI: 10.1016/j.cardfail.2009.12.016] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2009] [Revised: 10/22/2009] [Accepted: 12/17/2009] [Indexed: 11/19/2022]
Abstract
BACKGROUND Myocardial biopsy can be used for the detection of viral genome in dilated cardiomyopathy (DCM). Pilot studies have previously reported beneficial effects on clinical outcome and safety of an antiviral therapy using interferon beta-1b in chronic viral DCM. METHODS AND RESULTS Myocardial biopsies were taken from patients with DCM. Using polymerase chain reaction and Southern Blot analysis, viral genome could be detected in 49% of patients. In 42 patients with viral infection, off-label use with interferon beta-1b was initiated. A further 68 patients formed the control group. The outcome was evaluated after follow-up with echocardiography, exercise electrocardiogram, and New York Heart Association class. A total of 81 men and 29 women with a median left ventricular ejection fraction of 34% were included. The follow-up period was 36 months. In 33 (79%) patients with interferon beta-1b treatment, minor adverse reactions occurred, but no major adverse events were reported. No significant benefit for interferon beta-1b treatment on clinical outcome could be detected during follow-up. CONCLUSIONS Off-label use with interferon beta-1b in patients with viral DCM is feasible and safe under routine clinical practice. Concerning the herein evaluated clinical outcome parameters, promising results from pilot studies could not be confirmed. High prevalence of parvovirus B19 (92%) might influence the results.
Collapse
Affiliation(s)
- Oliver Zimmermann
- Department of Internal Medicine II - Cardiology, University of Ulm, Ulm, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Schabort EJ, Myburgh KH, Wiehe JM, Torzewski J, Niesler CU. Potential Myogenic Stem Cell Populations: Sources, Plasticity, and Application for Cardiac Repair. Stem Cells Dev 2009; 18:813-30. [DOI: 10.1089/scd.2008.0387] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Affiliation(s)
- Elske J. Schabort
- Department of Physiological Sciences, University of Stellenbosch, Stellenbosch, South Africa
| | - Kathryn H. Myburgh
- Department of Physiological Sciences, University of Stellenbosch, Stellenbosch, South Africa
| | - Juliane M. Wiehe
- Department of Internal Medicine II, University of Ulm, Ulm, Germany
| | - Jan Torzewski
- Cardiovascular Unit, Oberallgäu Kliniken GmbH, Immenstadt, Germany
| | - Carola U. Niesler
- Department of Biochemistry, School of Biochemistry, Genetics, Microbiology, and Plant Pathology, University of KwaZulu-Natal, Pietermaritzburg, South Africa
| |
Collapse
|
4
|
Wiehe JM, Ponsaerts P, Rojewski MT, Homann JM, Greiner J, Kronawitter D, Schrezenmeier H, Hombach V, Wiesneth M, Zimmermann O, Torzewski J. mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression. J Cell Mol Med 2007; 11:521-30. [PMID: 17635643 PMCID: PMC3922358 DOI: 10.1111/j.1582-4934.2007.00038.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Gene transfer into human CD34+ haematopoietic progenitor cells (HPC) and multi-potent mesenchymal stromal cells (MSC) is an essential tool for numerous in vitro and in vivo applications including therapeutic strategies, such as tissue engineering and gene therapy. Virus based methods may be efficient, but bear risks like tumorigenesis and activation of immune responses. A safer alternative is non-viral gene transfer, which is considered to be less efficient and accomplished with high cell toxicity. The truncated low affinity nerve growth factor receptor (ÄLNGFR) is a marker gene approved for human in vivo application. Human CD34+ HPC and human MSC were transfected with in vitro-transcribed mRNA for ΔLNGFR using the method of nucleofection. Transfection efficiency and cell viability were compared to plasmid-based nucleofection. Protein expression was assessed using flow cytometry over a time period of 10 days. Nucleofection of CD34+ HPC and MSC with mRNA resulted in significantly higher transfection efficiencies compared to plasmid transfection. Cell differentiation assays were performed after selecting ΔLNGFR positive cells using a fluorescent activating cell sorter. Neither cell differentiation of MSC into chondrocytes, adipocytes and osteoblasts, nor differentiation of HPC into burst forming unit erythroid (BFU-E) colony forming unit-granulocyte, erythrocyte, macrophage and megakaryocyte (CFU-GEMM), and CFU-granulocyte-macrophage (GM) was reduced. mRNA based nucleofection is a powerful, highly efficient and non-toxic approach for transient labelling of human progenitor cells or, via transfection of selective proteins, for transient manipulation of stem cell function. It may be useful to transiently manipulate stem cell characteristics and thus combine principles of gene therapy and tissue engineering.
Collapse
Affiliation(s)
- Juliane M Wiehe
- Department of Internal Medicine II, University of Ulm, Ulm, Germany
- *Correspondence to: Jan TORZEWSKI, University of Ulm; Department of Internal Medicine, II-Cardiology, Robert Koch Str. 8, 89081 Ulm, Germany. Tel: + 49 731 500-45026; Fax: + 49 731 500-45005; E-mail:
| | - Peter Ponsaerts
- Laboratory of Experimental Hematology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium
| | - Markus T Rojewski
- Institute for Transfusion Medicine, University of Ulm, and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, Ulm, Germany
| | - Joerg M Homann
- Department of Internal Medicine II, University of Ulm, Ulm, Germany
| | - Jochen Greiner
- Department of Internal Medicine III, University of Ulm, Ulm, Germany
| | | | - Hubert Schrezenmeier
- Institute for Transfusion Medicine, University of Ulm, and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, Ulm, Germany
| | - Vinzenz Hombach
- Department of Internal Medicine II, University of Ulm, Ulm, Germany
| | - Markus Wiesneth
- Institute for Transfusion Medicine, University of Ulm, and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, Ulm, Germany
| | | | - Jan Torzewski
- Department of Internal Medicine II, University of Ulm, Ulm, Germany
- *Correspondence to: Jan TORZEWSKI, University of Ulm; Department of Internal Medicine, II-Cardiology, Robert Koch Str. 8, 89081 Ulm, Germany. Tel: + 49 731 500-45026; Fax: + 49 731 500-45005; E-mail:
| |
Collapse
|